VetrixBio has presented first clinical data for VTX-304, an investigational antibody for dogs with osteoarthritis that the company says could combine pain relief comparable to bedinvetmab with cartilage protection.

The data was presented at the 6th International Veterinary Pain Short Course hosted at NC State College of Veterinary Medicine.

VTX-304 is a bispecific antibody designed to target NGF and ADAMTS-5.

In a natural OA model with aged Beagles with a mean age of 10.8 years, VTX-304, dosed at 2.5 mg/kg SC, delivered pain relief comparable to the anti-NGF monoclonal antibody bedinvetmab, as measured by the modified Canine Brief Pain Inventory.

VetrixBio says that in biochemical and cell-based studies, VTX-304 demonstrated potent NGF/TrkA pathway inhibition and effective blockade of ADAMTS-5-mediated aggrecan cleavage, consistent with cartilage protection.

Peter Hanson, Chief Scientific Officer at VetrixBio, said: "Pain and OA in dogs are multifactorial. Single-pathway therapies leave significant disease biology unaddressed.

"VTX-304 represents an important advance, anchoring analgesia to diseased joint biology while protecting cartilage integrity.

"These initial results show that our bispecific antibody has the potential to deliver superior therapeutic profiles in veterinary medicine."

https://www.vetrixbio.com